Close
Skip to main content
China

Published on

April 19, 2019

Last updated on

March 29, 2022

Health Food Temporarily Banned from Direct Selling

Health Foods & Supplements
Health Food Temporarily Banned from Direct Selling

On 14.02.2019, the MOFCOM suspended the filing and administrative approval of direct selling companies due to unreasonable promises with regards to health foods. In collaboration with the SAMR, MOFCOM is overhauling the health food market in China by optimizing the direct sales regulatory system.

Related News

Back to Main News Page
Two professionals in an office review documentation for a HealthScreen glucose monitor while examining a computer display showing a product label with model number, barcode, and QR code. One person points to the code on the screen as the other reads.
Malaysia

Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

Medical Devices
April 1, 2026
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Two office professionals sit at a desk in an office reviewing cosmetic and skincare product packaging alongside printed documents and binders. One person examines a product bottle while the other works on a laptop, suggesting regulatory compliance review.
Vietnam

Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens

Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.

Cosmetics
April 1, 2026
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.
Indonesia

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

Pharma & Biotech
April 1, 2026
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

Contact Our Consultants & Discover How We Can Support You

Let Cisema help turn your plans into reality.

Request Proposal